Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspirin + ibuprofen is a combination of two nonsteroidal anti-inflammatory drugs (NSAIDs): aspirin and ibuprofen. Both drugs act by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins, which are mediators of pain, inflammation, and fever. Aspirin irreversibly inhibits COX-1 and COX-2 enzymes, providing analgesic, antipyretic, anti-inflammatory effects as well as an antiplatelet effect at low doses. Ibuprofen reversibly inhibits the same enzymes and is primarily used for its analgesic and anti-inflammatory properties. The combination is not generally recommended due to increased risk of adverse effects such as gastrointestinal bleeding and attenuation of aspirin’s cardioprotective antiplatelet effect[1][2][3][5][8]. There are no widely marketed or approved pharmaceutical products that combine both agents in a single formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + ibuprofen.